Skip to main content

Advertisement

Figure 1 | BMC Cancer

Figure 1

From: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Figure 1

Group classifications coupled with response data based on the 180-gene GEPR to EGFR-targeted therapy. Patient populations from Khambata-Ford et al were classified using our predictive model. Percentage of patients exhibiting each annotated radiographic responses (CR/PR – complete responses and partial responses, SD – stable disease, PD – progressive disease, NA – not available/not reported) are classified as 'sensitive' or 'resistant' groups. A: KRAS-wildtype patients (43 subjects); B: all patients (80 subjects); and C: KRAS-mutant patients (27 subjects).

Back to article page